University of Alberta
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ualberta.ca
Clinical Trials
773
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (659 trials with phase data)• Click on a phase to view related trials
Adipose Tissues and Liver Changes Associated Semaglutide in CKD
- Conditions
- Chronic Kidney Disease in Type 2 Diabetes
- Interventions
- First Posted Date
- 2025-09-23
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 62
- Registration Number
- NCT07187830
- Locations
- 🇨🇦
Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada
Connecting Today to Combat Social Isolation and Loneliness
- Conditions
- Dementia in Nursing HomeFamilyRemote Visits
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-23
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 320
- Registration Number
- NCT07182019
Sotatercept in Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- First Posted Date
- 2025-08-24
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 27
- Registration Number
- NCT07140484
A Game-based Screening for MCI Detection in Older Adults
- Conditions
- Mild Cognitive Impairment (MCI)
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-08-22
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 59
- Registration Number
- NCT07137650
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Language Translation of Knowledge Mobilization Resources
- Conditions
- Communication Research
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 350
- Registration Number
- NCT07127887
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 155
- Next
News
Onco-Innovations Partners with University of Alberta to Advance PNKP Inhibitor Research for Glioblastoma Treatment
Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme.
World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival
A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.
Onco-Innovations Initiates Manufacturing of PNKP Inhibitor for Preclinical Testing
Onco-Innovations has partnered with Dalton Pharma Services to begin manufacturing 50 grams of their proprietary PNKP inhibitor A83B4C63 for preclinical testing.
University of Alberta's Novel Cancer Drug Zelenirstat Receives FDA Fast-Track Designation
University of Alberta researchers have developed Zelenirstat, an innovative oral cancer medication that works by preventing cancer cell spread and starving tumors.